Skip to content

US · QNTM · BIOTECHNOLOGY

Quantum BioPharma Ltd. (QNTM) intrinsic value and stock valuation

$1.29as of 2026-11-21 · Mkt cap 22.08M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Quantum BioPharma Ltd. DCF and intrinsic value

InvestorsCraft values QNTM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from QNTM’s statements →

Quantum BioPharma Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Toronto, ON M5C 2V9 quantumbiopharma.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-26.18M
20152025
Free cash flow
-$-8.38M
20152025
Total equity
$5.09M-32.5% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-15.3M-$-16.14M-$-23.79M-$-27.43M-$-33.74M
Net income-$-26.18M-$-14.2M-$-17.9M-$-23.61M-$-35.29M
EPSd-$-7.96M-$-12.46M-$-29.34M-$-39.35M-$-65.35M
Operating cash flow-$-8.38M-$-6.88M-$-10.83M-$-28.33M-$-20.75M
Capital expenditure$0.00$0.00$0.00-$-360K-$-500K
Free cash flow-$-8.38M-$-6.88M-$-10.83M-$-28.7M-$-21.25M
Total assets$11.1M$17.1M$17.5M$38.4M$63M
Total debt$1.87M$820K$340K$520K$560K
Net debt-$-30K-$-5.17M-$-2.42M-$-16.46M-$-34.7M
Total equity$5.09M$10.4M$12.9M$30.5M$54.1M
Cash and short-term investments$6.17M$7.2M$3.51M$17M$35.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$2.76M$6.08M$3.86M$6.91M$6.33M
Selling, general and administrative expenses$12M$9.31M$13.2M$16M$23.4M
Other expenses$530K$740K$6.73M$4.54M$4.05M
Operating expenses$15.3M$16.1M$23.8M$27.4M$33.7M
Cost and expenses$15.3M$16.1M$23.8M$27.4M$33.7M
Interest income$240K$570K$790K$370K$0.00
Interest expense$620K$50K$0.00$50K$70K
Depreciation and amortization$550K$490K$2.51M$4.54M$4.05M
Ebitda-$-25.79M-$-14.38M-$-15.72M-$-22.12M-$-29.82M
Operating income-$-15.3M-$-16.14M-$-23.79M-$-27.43M-$-33.74M
Total other income/expenses, net-$-11.65M$1.22M$5.56M$730K-$-190K
Income before tax-$-26.96M-$-14.92M-$-18.23M-$-26.7M-$-33.94M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.18M-$-14.2M-$-17.9M-$-23.61M-$-35.29M
Weighted average shares outstanding$3.29M$1.14M$610K$600K$540K
Weighted average diluted shares outstanding$3.29M$1.14M$610K$600K$540K
Balance sheet
20252024202320222021
Cash and short-term investments$6.17M$7.2M$3.51M$17M$35.4M
Net receivables$230K$3.81M$7.42M$370K$500K
Inventory$50K$120K$0.00$0.00$0.00
Total current assets$6.47M$12.1M$11.1M$17.9M$45.9M
Property, plant and equipment, net$170K$130K$120K$260K$170K
Goodwill and intangible assets$4.5M$4.93M$5.36M$12M$16.2M
Long-term investments$0.00$0.00$10K$830K$660K
Total non-current assets$4.67M$5.07M$6.39M$20.6M$17M
Total assets$11.1M$17.1M$17.5M$38.4M$63M
Accounts payable$0.00$3.25M$3.24M$2.76M$3M
Short-term debt$1.87M$820K$340K$480K$420K
Deferred revenue$0.00$1M$0.00$0.00$0.00
Total current liabilities$6.05M$6.68M$4.57M$7.83M$8.7M
Long-term debt$0.00$0.00$0.00$40K$130K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$40K$130K
Capital lease obligations$0.00$50K$40K$220K$260K
Total liabilities$6.05M$6.68M$4.57M$7.87M$8.83M
Common stock$169.4M$150.5M$137.8M$143.4M$152.3M
Retained earnings-$-197.93M-$-172.11M-$-157.91M-$-144.16M-$-126.15M
Accumulated other comprehensive income (loss)$100K$50K$420K$650K$240K
Total equity$5.09M$10.4M$12.9M$30.5M$54.1M
Total investments$4.27M$1.2M$760K$850K$820K
Total debt$1.87M$820K$340K$520K$560K
Net debt-$-30K-$-5.17M-$-2.42M-$-16.46M-$-34.7M
Cash flow statement
20252024202320222021
Net income-$-26.18M-$-14.92M-$-18.23M-$-26.7M-$-33.94M
Depreciation and amortization$560K$490K$2.51M$4.53M$4.05M
Stock-based compensation$2.95M$150K$3.84M$1.53M$7.44M
Change in working capital$2.02M$9.76M$1.64M-$-7.12M$2.89M
Accounts receivable$1.72M$4.52M-$-730K-$-7.22M-$-110K
Inventory$70K-$-120K$0.00$0.00$0.00
Accounts payable$1.2M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-8.38M-$-6.88M-$-10.83M-$-28.33M-$-20.75M
Investments in property, plant and equipment$0.00$0.00$0.00-$-110K-$-500K
Acquisitions, net$0.00$0.00$30K$0.00$770K
Net cash used for investing activities-$-1.99M-$-1.5M-$-270K$12.1M$270K
Common stock issued$540K$10.7M$0.00$0.00$38.3M
Common stock repurchased$0.00$0.00-$-2.96M-$-1.93M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.21M$11.6M-$-3.13M-$-2.07M$38.2M
Net change in cash-$-4.09M$3.24M-$-14.22M-$-18.28M$17.7M
Cash at end of period$1.9M$6M$2.76M$17M$35.3M
Operating cash flow-$-8.38M-$-6.88M-$-10.83M-$-28.33M-$-20.75M
Capital expenditure$0.00$0.00$0.00-$-360K-$-500K
Free cash flow-$-8.38M-$-6.88M-$-10.83M-$-28.7M-$-21.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Quantum BioPharma Ltd.

        Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.

        CEO
        Zeeshan Saeed
        Employees
        17
        Beta
        0.44

        Explore

        Frequently asked questions

        What is the intrinsic value of Quantum BioPharma Ltd. (QNTM)?

        InvestorsCraft does not currently publish an intrinsic value for QNTM. How the IC value is calculated.

        Is QNTM undervalued?

        InvestorsCraft does not publish an undervaluation signal for QNTM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.